Better benefits start here
At Prime, we’re focused on redefining our company and how we deliver integrated drug management to support the needs of clients and the members they serve. Dave Schlett, President, PBM Solutions, shares his thoughts about what we accomplished in 2022, and where we are headed in 2023.
Prime’s owner clients
Blue Cross and Blue Shield of Alabama
Blue Cross and Blue Shield of Kansas
Blue Cross and Blue Shield of Minnesota
Blue Cross and Blue Shield of Nebraska
Blue Cross and Blue Shield of North Carolina
Blue Cross Blue Shield of North Dakota
Blue Cross Blue Shield of Rhode Island
Blue Cross Blue Shield of Wyoming
Health Care Services Corporation (HCSC)
Blue Cross and Blue Shield of Illinois
Blue Cross and Blue Shield of Texas
Blue Cross and Blue Shield of Oklahoma
Blue Cross and Blue Shield of New Mexico
Blue Cross and Blue Shield of Montana
Regence Health Plans
Regence Blue Shield Idaho
Regence Blue Cross Blue Shield of Oregon
Regence Blue Cross Blue Shield of Utah
Regence Blue Shield Washington
PRIME AND MAGELLAN RX
Joining forces for a brighter future
Prime Therapeutics closes $1.35 billion Magellan Rx acquisition, uniting pharmacy and medical drug management expertise. The combination creates an opportunity to transform the industry by driving affordability and integrating whole-person care to enhance the patient, provider and customer experience.
As Vice President of Consultant Relations at Prime Therapeutics (Prime), Ann O’Brien oversees consultant business strategy and creates opportunities for growth in the self-insured payor market.
As Consultant Engagement Director at Prime Therapeutics (Prime), Joe Chamberlin is responsible for managing the relationships between Prime and its consultant partners.
Our executive leadership team (ELT) develops Prime’s strategy and works to create the right conditions for employees to successfully execute on that strategy. They bring a deep understanding of the marketplace and dedication to Prime’s purpose to their important role in guiding both employees and clients toward success.
Driving greater use of biosimilars to help lower drug costs
As part of our total drug management strategy, we actively promote evidence-based use of biosimilars (and other low-cost drug options) that are endorsed by our Phamracy and Therapeutics Committee.
We take an integrated, channel-optimized, approach to design people-centered products that help manage cost and provide smarter care.
We’re unlocking the potential of integrated drug management to help lower costs and deliver better outcomes.
Built on a unique business model we’ve become a leading integrated drug management company.
March 30, 2023
Drug oversupply, or stockpiling, due to overlapping drug refills can cause unnecessary drug costs
If you have a chronic condition, your pharmacy may notify you advance of…
March 28, 2023
Biosimilars are at the door, Part 3
News about biosimilars is everywhere. Sometimes you just need the basics. This four-part…
March 27, 2023
Specialty Drug Pipeline Update: March 2023
This monthly pipeline wrap-up provides a review of newly approved specialty drugs, recent…
Each Blue Cross® and/or Blue Shield® plan is an independent licensee of the Blue Cross and Blue Shield Association.